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HIV and malaria have similar global distributions. Annually, 500 million are infected and 1 million die because of malaria. 33
million have HIV and 2 million die from it each year. Minor eﬀects of one infection on the disease course or outcome for the other
would signiﬁcantly impact public health because of the sheer number of people at risk for coinfection. While early population-
based studies showed no diﬀerence in outcomes between HIV-positive and HIV-negative individuals with malaria, more recent
work suggests that those with HIV have more frequent episodes of symptomatic malaria and that malaria increases HIV plasma
viral load and decreases CD4+ T cells. HIV and malaria each interact with the host’s immune system, resulting in a complex
activation of immune cells, and subsequent dysregulated production of cytokines and antibodies. Further investigation of these
interactions is needed to better deﬁne eﬀects of coinfection.
Copyright © 2009 S. Hochman and K. Kim. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
HIV and malaria have similar global distributions, with
the majority of those aﬀected living in sub-Saharan Africa,
the Indian subcontinent, and Southeast Asia. Given the
overlap of their geographic distribution and resultant rates
of coinfection, interactions between the two diseases pose
major public health problems. Together they accounted for
over 3 million deaths in 2007 [1, 2], and millions more are
adversely aﬀected each year. Malaria and HIV/AIDS are both
diseases of poverty and contribute to poverty by aﬀecting
young people who would otherwise enter the workforce and
contribute to the local economy.
Malaria is caused by the protozoan parasite Plasmodium
and is transmitted by Anopheles mosquitoes. It is endemic in
most tropical and subtropical regions of the world. Of the
four Plasmodium species that infect humans, P. falciparum
is the most virulent and is responsible for the majority of
morbidity and mortality due to malaria. Worldwide, 1.2
billion people are at risk for malaria infection, resulting in
500 million infections and more than 1 million deaths each
year. The majority of these deaths occur in young children
in sub-Saharan Africa, where one in every ﬁve childhood
deaths is due to malaria [1]. Aside from young children,
pregnant women are also heavily aﬀected [3], with resultant
eﬀects on maternal health and birth outcomes. While recent
data indicates the number of malaria infections per year is
decreasing (247 million malaria cases in 2006) the number
of deaths attributable to malaria remains unchanged [4].
Areas of the world with high rates of malaria also carry
a heavy burden of HIV. There are 33 million people living
withHIVworldwide,with22.5millioninsub-SaharanAfrica
alone. This results in an estimated overall prevalence of
5% in sub-Saharan Africa, with some countries reporting
prevalence rates of greater than 25%. While new HIV
infections in adults and children have decreased since 2005,
there were an estimated 2.5 million children living with HIV
in 2007, nearly 90% of whom are in sub-Saharan Africa. It
is estimated that 2.1 million deaths in 2007 were due to HIV,
of which 1.6 million occurred in sub-Saharan Africa, making
HIV/AIDS the number one cause of mortality in that region
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2.PhysiologicImpactof Malaria
Falciparum malaria has a spectrum of clinical presentations,
ranging from asymptomatic parasitemia in patients with
immunity to severe anemia, cerebral malaria, multiorgan
failure, or death.
Anemia is most frequently seen in young children and
pregnant women [5] and can be seen in acute infection
as well as with chronic repeated malarial infections. The
underlying causes of severe malarial anemia are likely
multifactorial. Extravascular and/or intravascular hemolysis
of both infected and uninfected erythrocytes plays a role:
changes in surface proteins on infected erythrocytes lead to
increased clearance of these cells [6], while noninfected red
blood cells are destroyed in the spleen during acute infection
[7]. This leads to hemolysis and depletion of iron stores.
Bone marrow suppression also plays an important role in
the pathogenesis of malarial anemia. The normal response
to hemolytic anemia is enhanced secretion of erythropoietin,
leading to stimulation of erythropoiesis, but this mechanism
seems to be defective in patients with malaria. During acute
infection, abnormalities are seen in erythroid progenitors
[8], while dyserythropoiesis (abnormal production of red
cells) is observed in chronic infection [9].
Cerebral malaria and other end-organ damage is medi-
ated through interactions between infected red blood cells
and host receptors on the blood vessel wall, resulting in
adherence and sequestration of infected red blood cells in
the postcapillary venules, obstruction of blood ﬂow, and
subsequenttissuedamage[10].Patientswhosurvivecerebral
malaria may suﬀer from long-term mental and psychological
deﬁcits [11]. Renal complications are common and may
presentasacuterenalfailureduetotheeﬀectsofsequestrated
infected red blood cells or with nephrotic syndrome, due to
deposition of antigen-antibody complexes within glomeruli.
P. falciparum can also result in severe anemia, low birth
weight, and maternal death during pregnancy [3, 12].
3.PhysiologicImpactof HIV
HIV infects and depletes CD4+ T lymphocytes, putting
patients at risk for opportunistic infection and malignancy,
the major causes of death due to HIV and AIDS. However,
it also has eﬀects on the systemic inﬂammatory response,
causing activation and/or apoptosis in a variety of immune
cells as well as elevated levels of proinﬂammatory cytokines
and chemokines in plasma and lymph nodes. This immune
activation, rather than being a reﬂection of antiviral immu-
nity, is associated with HIV-1 disease progression [13]. It is
also a potential means by which HIV aﬀects disease course
and outcome in other infections, such as malaria.
4. Impact of HIV and MalariaCoinfection
Whilenopopulation-basedstudiesareavailabletodetermine
the number of patients aﬀected by coinfection and the
impact of coinfection on a population, a mathematical
model applied to previously published data was used to
estimate the impact of HIV-1 on malaria in sub-Saharan
Africa. It estimated that an additional 3 million cases
of malaria and 65000 additional malaria-related deaths
annually are due to the impact of HIV [14]. Rates were
highest in countries with high HIV prevalence and unstable
malaria transmission.
Cohort studies have shown that malaria infection causes
an increase in plasma HIV viral load, even during asymp-
tomatic parasitemia. HIV viral load returned to baseline
eightweeksafteracutemalariainfection[15].Ithasalsobeen
demonstrated that CD4+ T lymphocytes decline temporarily
during clinical malaria episodes in HIV-infected and HIV-
uninfected patients [16] and that repeated malaria infections
are associated with a more rapid decline in CD4+ T
lymphocytesovertime[17],suggestingthatmalariamaylead
to faster disease progression from HIV to AIDS.
While early studies found no association between HIV
and malaria disease severity in either adults or children
[18, 19] more recent research has shown that HIV infection
predisposes to more frequent episodes of symptomatic
malaria [20] and more episodes of severe or complicated
malaria including death in both children and adults [21–
24], see Table 1. An inverse relationship was found between
incidence of severe malaria and CD4+ T lymphocyte counts.
Generally, patients with HIV respond to standard malaria
regimens. While infection with HIV has been associated
with an increased rate of malaria treatment failure, this was
due to re-infection with new malaria strains, rather than
recrudescence of prior infection [20].
In HIV-uninfected women, risk for symptomatic or
placental malaria decreases with each subsequent pregnancy.
In HIV-infected women this gravidity-speciﬁc pattern is
altered, such that multigravidae women carry the same
risk of disease as primigravidae women [25]. Pregnancy-
associated malaria is associated with increased risk of mater-
nal anemia, intrauterine growth restriction, and delivery of
preterm,andlow-birth-weight infants[26].Giventhe lackof
gravidity-speciﬁc protection against malaria seen with HIV
infection in pregnant women, HIV puts more pregnancies at
risk for complications associated with malaria.
In a cohort study in Kenya, HIV-coinfected women
had higher placental parasite densities and higher rates of
antenatal malaria transmission than did HIV-uninfected
women [26]. Maternal antibody to variant surface anti-
gens (VSAs) on malaria-infected erythrocytes plays an
important role in pregnancy-related immunity to malaria.
Sera from HIV-infected mothers when analyzed by ﬂow
cytometry contained fewer antibodies to VSAs in both
placental and pediatric isolates of malaria than did sera
from HIV-uninfected mothers [27]. Additionally, assays
using plasma or puriﬁed IgG from HIV-infected or HIV-
uninfected primi- or multigravidae women found that HIV-
uninfected multigravidae women had high levels of opsonic
phagocytosis of infected erythrocytes, which was due to
IgG1 and IgG3 speciﬁc for VSA. Opsonic phagocytosis
was not seen with plasma or puriﬁed IgG from HIV-
uninfected primigravidae women or HIV-uninfected men.
HIV-infected multigravidae women had signiﬁcantly lower
plasma opsonizing activity than did their HIV-uninfected
counterparts [28].Interdisciplinary Perspectives on Infectious Diseases 3
Table 1: Eﬀects of coinfection with HIV and malaria.
Interactions
Type of Interaction Pregnant women Children Adult men and nonpregnant
women
Eﬀect of HIV on malaria
•↑Risk of infection + ? +
•↑Parasite density + ? +
Eﬀect of malaria on HIV
•↑Viral load + ? +







(No deﬁnitive data, although ↑ viral
load has previously been shown to
correlate with ↑ sexual
transmission)
Eﬀects of dual infection
•↑Severity of illness ++ +
•↑Frequency and severity of anemia ++ +
•↑Frequency of low birth weight +N / A N / A
Cohort studies in Cameroon show that malaria infection
during pregnancy may increase the risk of mother-to-child
transmission of HIV [29, 30]. One potential mechanism for
this was evaluated in vitro, where binding of recombinant
P. falciparum adhesin to chondroitin sulfate A on human
placental cells increased HIV-1 replication in those cells,
possibly via TNF-alpha stimulation [31].
5. ImmuneResponse to Malaria
Proinﬂammatory (Th1) cytokines such as TNF-alpha are
thought to play an important role in malaria pathogenesis
and in cerebral malaria in particular, as they increase
surface expression of adhesion molecules on endothelial
cells, promoting parasite attachment. Activated CD4+ T
lymphocytes stimulate macrophages to produce TNF-alpha,
which leads to cerebral malaria in mouse models [32].
In humans, clusters of cytokines may help discriminate
between mild, severe, and cerebral malaria. In an adult
population in a malaria-endemic region of India, high levels
of IL-12, IL-5, and IL-6 discriminated severe forms of
malaria from mild malaria. Levels of IL-1beta, IL-12, and
IFN-gamma helped to discriminate cerebral malaria from
severe malaria, with high IL-1beta levels being associated
with cerebral malaria, and high IL-12 and IFN-gamma levels
being associated with severe malaria [33]. In a pediatric
population in Mali, high levels of IL-6 and IL-10 helped
to discriminate both severe malaria from mild malaria and
cerebral malaria from severe malaria, whereas IL-1beta and
IL-12 did not diﬀer signiﬁcantly among groups [34]. While
there are many studies that associate patterns of cytokines
to disease, results may be diﬀerent depending on the cohort
population. Thus, there is an association between elevations
in certain cytokines and disease outcomes, but it is hard to
generalize these associations to diﬀerent patient populations.
Adaptive immunity to malaria is thought to confer
protection against febrile parasitemia but does not prevent
parasitemia. This is due in part to the development of
antibodies against proteins on the infected erythrocyte
surface, notably VSA [35].
The eﬀect of malaria on dendritic cells, key players
in both the early stages of adaptive immunity and innate
immunity, is not clear. Urban et al. found that P. falciparum-
infectederythrocytesadheretohumandendriticcells,inhibit
their maturation, and subsequently reduce their capacity
to stimulate T cells [36]. However, mouse studies using
P. chabaudi found that infected erythrocytes induce matu-
ration of dendritic cells, stimulate IL-12 and IFN-gamma
production, and cause CD4+ T lymphocyte proliferation
[37]. While these two studies reported conﬂicting ﬁndings,
one unifying explanation for both was seen in another
mouse model, using P. yoelii. Overstimulation of dendritic
cells by toll-like receptors makes them refractory to further
activationinP. yoelii-infectedmice[38].Asmalariainfection
progresses and parasitemia increases exponentially, dendritic
cells will develop toll-like receptor resistance. This would
resultindendriticcelldysfunctioninlaterstagesofinfection,
aswasseenbyUrbanetal.,whiletheﬁndingsofIngetal.may
be more consistent with the early stages of malaria.
6. Immune Response to HIV
Proinﬂammatory cytokines play an important role both in
control and pathogenesis of HIV infection. During infection,
viral particles are taken up by antigen presenting cells
(APCs), which are then recognized by CD4+ T lymphocytes,
causing activation and release of IL-2 and IFN-gamma.
These proinﬂammatory cytokines in turn stimulate CD8+
T lymphocytes, which control viremia. It is not known if
this inﬂammatory response seen in HIV has an eﬀect on
the adherence and sequestration seen in malaria. However,
HIV upregulates adhesion molecules on endothelial cells,
which may compound the adherence and sequestration seen
in malaria [39].4 Interdisciplinary Perspectives on Infectious Diseases
HIV also dysregulates pathways of cytokine expression,
such that production of the proinﬂammatory cytokines IL-
12 and IFN-gamma is decreased and expression of the
anti-inﬂammatory cytokine IL-10 is increased [40]. As HIV
progresses clinically to AIDS there are eﬀects on innate
immunity, with progressive loss of T lymphocyte responses
to common recall antigens [41]. Increased IL-10 has been
shown to play a role in this impaired innate immune
response in AIDS patients [42].
The impaired innate immune response in patients with
AIDS may in part account for the increased rates of
symptomatic malaria seen in cohort studies. However, the
decreased production of IL-12 and IFN-gamma seen in HIV
is confounding, as high levels of these proinﬂammatory
cytokinesareassociatedwithseveremalariainclinicalstudies
[33], and previously mentioned cohort studies have found
higher rates of severe or symptomatic malaria in subjects
with HIV.
Increased expression of IL-10 also appears to play a
role in loss of adaptive immunity. IL-10 impairs T helper
type 1 (Th1) responses [42]. Dendritic cells In HIV/AIDS
are functionally impaired, producing less IL-12 and more
IL-10, disrupting the IL-12/IFN-gamma signaling pathway
and contributing to problems with adaptive immunity [40].
It is not clear if this impairment is due to direct HIV
infection of dendritic cells, or that indirect eﬀects of chronic
antigenic stimulation or exposure to virally induced proteins
cause dendritic cell dysfunction. Given the important role of
dendritic cells in adaptive immunity to malaria, the eﬀects of
HIV on dendritic cell dysfunction may also contribute to the
higher frequency of symptomatic parasitemia seen in cohort
studies.
7. Effects of Malaria on the Endothelium and
Blood-Brain Barrier
Cerebral malaria is a major cause of death due to P.
falciparum in children under the age of ﬁve. Characterized
by coma and/or seizures, it is associated with sequestration
of parasitized red blood cells in the brain microvasculature.
Occasionally brain edema and elevated intracranial pressure
are seen.
Postmortem samples from children who died from
cerebral malaria show activation of endothelial cells (with
upregulation of ICAM-1) and macrophages (with increased
macrophage scavenger receptor and sialoadhesin), and
disruption of endothelial intercellular junctions (ZO-1,
occludin, vinculin) in vessels containing sequestered par-
asitized red blood cells. No leakage of plasma proteins
(ﬁbrinogen, C5b-9, IgG) into brain parenchyma was seen,
suggesting that the blood-brain barrier remains intact. How-
ever, there were elevations in cerebrospinal ﬂuid albumin
taken prior to death, which may indicate blood-brain barrier
permeability [43].
In vitro studies have backed up some of these ﬁndings.
Gillrie et al. showed that parasite sonicates but not intact
malaria-infected red blood cells disrupt the endothelial
(dermal and pulmonary, not brain) barrier, revealed by
discontinuous immunoﬂuorescent staining of endothelial
junction proteins, formation of interendothelial gaps in
monolayers,andlossintotalproteincontentofclaudin5and
redistribution of ZO-1 [44].
Additionally it appears that severity of malaria infection
is associated with diﬀerential expression of tight junction
proteins. Quantitative PCR of human umbilical vascular
endothelial cells (HUVECs) cultured with P. falciparum
samples from patients with uncomplicated malaria showed
increased mRNA levels of occludin, vinculin, and ZO-
1. Those cultured with samples from severe malaria had
no change in mRNA levels, and HUVECs cultured with
P. falciparum from patients with cerebral malaria had
decreased mRNA levels of occludin, vinculin, and ZO-
1[ 45]. This data suggests that infected erythrocytes can
alter the expression of tight junction proteins in endothelial
cells at the site of sequestration, inﬂuencing disease sever-
ity.
Not only are endothelial junction proteins aﬀected, but
also endothelial cells themselves seem to be inﬂuenced by
infected erythrocytes, producing inﬂammatory mediators
in response to malaria infection. Endothelial cells produce
tissue factor when cultured with P. falciparum,a n db r a i n
endothelial cells from patients dying of cerebral malaria
and from those with malaria who died of other causes
also showed increased levels of tissue factor [46]. Tissue
factor plays a role in coagulation via thrombin formation,
and plays a role in inﬂammation, as it is upregulated by
proinﬂammatory cytokines such as TNF-alpha and also
induces expression of such cytokines [47].
Endothelial cells also upregulate adhesion molecules in
the setting of falciparum malaria. In P. falciparum isolates
from patients with complicated malaria, binding of infected
redbloodcellstohumanlungmicrovascularendothelialcells
was observed and was primarily mediated through ICAM-
1 and chondroitin sulfate (CSA) [48]. Mouse models of
cerebral malaria have supported the role of ICAM-1. ICAM-
1-deﬁcient C57BL/6 mice infected with P. berghei ANKA
were protected from mortality compared with C57BL/6
controls [49]. Additionally, lack of TNF receptor 2 con-
ferred resistance to cerebral malaria in mice, thought to
be due to blocking the upregulatory eﬀects of TNF on
ICAM-1 expression in brain microvascular endothelial cells
[50].
Another adhesion molecule that is likely involved in
cerebral malaria pathogenesis is CD36, a receptor with a
wide tissue distribution that is also found on endothelial
cells. Monoclonal antibodies to CD36 and ICAM-1 partially
inhibited the binding of P. falciparum-infected red blood
cells to human brain endothelium, suggesting that both are
important for cytoadherence [51]. The rodent malaria strain
P. chabaudi has been used to study malaria sequestration in
mice, and P. chabaudi AS-infected red blood cells adhered
to puriﬁed CD36 in vitro [52]. This is of particular interest
when considering the role of HIV coinfection in malarial
sequestrationandeﬀectsontheblood-brainbarrier,asCD36
expression on circulating monocytes is signiﬁcantly higher
in HIV-1 infected patients compared with healthy controls
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8. Effects of HIV on the Endothelium and
Blood-Brain Barrier
Unlike malaria, HIV is known to invade and infect the brain
parenchyma, causing HIV-associated encephalitis and/or
HIV-associated dementia. HIV may infect astrocytes at low
levels, and it can activate endothelial cells, but it does
not infect endothelial cells. HIV is thought to enter brain
parenchyma through the regulated transmigration of HIV-
infected mononuclear cells across the blood-brain barrier,
mediated by surface receptors on endothelial cells such as
ICAM-1. Once across the barrier, HIV-infected cells recruit
microglia and astrocytes, allowing for subsequent infection
of these cells and spread of HIV within the CNS.
As HIV replicates within the CNS, it produces inﬂam-
matory mediators, including the chemokine CCL2/MCP-1
[54]. This chemokine has been shown to enhance blood-
brain barrier permeability, with increased transmigration
of HIV-infected monocytes and a loss of tight junction
proteins [55]. In addition to CCL2/MCP-1, cytokines
including TNF-alpha, IFN-gamma, IL-1beta, and IL-6 are
increased in brain tissue and CSF of people with NeuroAIDS
[54].
9. DrugEffects
Aspartic proteases play key roles in HIV and are thus
important therapeutic drug targets. Aspartic proteases are
also important in malaria parasites (as plasmepsins), and
antiretroviral protease inhibitors seem to have both direct
eﬀects on Plasmodium and indirect eﬀects related to cytoad-
herence and phagocytosis.
The antiretroviral protease inhibitors saquinavir,
ritonavir, indinavir, nelﬁnavir, amprenavir, lopinavir,
and atazanavir directly inhibit erythrocytic stages of P.
falciparum grown in vitro at concentrations achieved in
vivo [56, 57], and mice infected with P. chabaudi AS had
a delay in patency and attenuation of parasitemia when
given oral ritonanvir/saquinavir or ritonavir/lopinavir
[58]. Some antiretrovirals also seem to exert an eﬀect on
the pre-erythrocytic stages of malaria. Using P. berghei,a
rodent strain of malaria, saquinavir and lopinavir inhibited
development of extra-erythrocytic liver stages in vitro. In
vivo mouse studies using the rodent strain P. yoelii showed a
reduction in liver parasite burden when lopinavir/ritonavir
was administered [59].
The antiretroviral protease inhibitors ritonavir and
saquinavir aﬀect CD36-mediated cytoadherence, thought
to play a role in cerebral malaria and other end-organ
damage in severe malaria. The drugs decrease CD36 surface
concentrations on C32 epithelial cells in culture, which
was associated with a decrease in cytoadherence of para-
sitized erythrocytes [60]. No eﬀe c to nI C A M - 1e x p r e s s i o n
on cells was seen. In addition, these protease inhibitors
aﬀect nonopsonic phagocytosis of parasitized erythrocytes.
Human macrophages exposed to ritonavir or saquinavir also
had reduced surface values of CD36, with an associated
decrease in nonopsonic phagocytosis. The NNRTI nevirap-
ine had no eﬀect on CD36 concentrations on either C32
cells or macrophages and did not aﬀect cytoadherence or
phagocytosis.
The antimalarial drug chloroquine has eﬀects on HIV,
inhibiting the production of infectious viral particles by
impairing virus glycosylation. Chloroquine also has syn-
ergistic eﬀects on HIV suppression with the protease
inhibitors indinavir, ritonavir, and saquinavir at concentra-
tions achieved with prophylaxis dosing [61]. In vitro studies
have also shown a synergistic eﬀect on malaria growth
between the protease inhibitors ritonavir and saquinavir and
both chloroquine and meﬂoquine [62].
An additional drug-related interaction between malaria
and HIV involves the use of trimethoprim-sulfamethoxazole
prophylaxis in HIV-infected patients. In rural Uganda, HIV-
infected participants given trimethoprim-sulfamethoxazole
had a 76% decrease in rates of malaria compared with when
they were not receiving trimethoprim-sulfamethoxazole,
and participants who received antiretroviral therapy plus
trimethoprim-sulfamethoxazole had a 92% decrease in
malaria rates [63]. It is important to note that the antiretro-
viral regimen used did not include a protease inhibitor.
10. Conclusions
Malaria and HIV aﬀect millions of people across overlapping
geographic distributions, and risk of transmission of both
malaria and HIV may be increased due to coinfection. It has
been observed that HIV-infected people in areas of malaria
transmission have more frequent episodes of symptomatic
parasitemia [20] and higher parasitemias than those without
HIV [64]. Thus, there is likely a higher risk for increased
transmission of malaria in these areas. Additionally, HIV-
infected people have an increase in viremia during episodes
of parasitemia [15, 65], leading to a potential increase in
risk of HIV transmission. Given the sheer numbers of people
livingwithHIVinsub-SaharanAfrica,anareawheremalaria
transmission is common, there is concern for a signiﬁcant
public health threat.
While some interactions between malaria and HIV are
known, these interactions have not been extensively studied
from an epidemiological perspective. Many aspects of the
relationship between malaria and HIV remain unanswered.
While malaria is a major cause of morbidity and mortality
in children in sub-Saharan Africa [1], little is known
regarding the contribution of HIV to rates of severe malaria,
cerebral malaria, and malaria deaths in these children.
Additionally, the ﬁndings of increased rates of symptomatic
malaria, higher parasite densities, and poorer responses
to malaria treatment in adults have not been studied in
children.
While it is known that pregnant women with HIV have
higher rates of symptomatic malaria [25], placental malaria,
and malaria transmission to their children [26], it is not
known if mother-to-child transmission of HIV is aﬀected
by malaria infection. And while it has been shown that
malaria infection increases HIV viral load [15], it has yet
to be demonstrated if this translates to higher rates of6 Interdisciplinary Perspectives on Infectious Diseases
HIV transmission among populations. Additionally, it is not
known if HIV increases rates of malaria transmission, even
though it has been shown that HIV increases parasite density
during malaria infection.
It is also unclear if HIV and malaria coinfection have an
impact on treatment or clinical outcomes. Does HIV have an
eﬀect on resistance to antimalarial drugs, and are there more
eﬀective drugs to treat malaria in those who are also infected
with HIV? Are there interactions between antiretrovirals
used for HIV and antimalarial drugs currently in use, such
as artemesin-derivatives? Also important to study are the
eﬀects of malaria on HIV prognosis: do the increases in
viral load and decreases in CD4+ T lymphocytes seen during
acute malaria infection have long term consequences on HIV
progression to AIDS? These questions deserve investigative
attention.
In addition to the need for population-based studies of
coinfection, microbe-microbe interactions deserve further
research eﬀorts as well. It is likely that HIV and P. falci-
parum have a synergistic relationship, as both provoke an
inﬂammatory response from immune cells, with subsequent
eﬀects on endothelial activation and blood-brain barrier
permeability. Investigative methods that adequately mimic
these pertinent clinical scenarios are needed. Thus, eﬀorts to
coculture malaria and HIV, and to observe the eﬀects of each
microbe during coculture, should be pursued. Examining
the interactions between malaria and HIV in the setting
of immune cells, endothelial models, and models of the
blood-brain barrier would shed light on the eﬀects on
immune dysregulation, endothelial activation, and blood-
brain barrier permeability.
Eﬀective animal models of coinfection are also needed
to look at systemic inﬂammatory responses and eﬀects on
end-organ damage, especially pertaining to cerebral malaria.
While no animal model can fully mimic the eﬀects of HIV
and malaria coinfection in humans, it is impractical to
invasively study dual infection in humans in a controlled,
monitored setting. Established murine models of cerebral
malaria rely on altered endothelial cell function and the
immune response, both of which play a pivotal role in
human disease [66]. A pertinent murine model of HIV
infection and end-organ damage is the transgenic HIVJR-CSF
model, which has been used to study blood-brain barrier
integrity [67]. Integrating these two models would allow for
the development of an eﬀective mouse model for HIV and
malaria coinfection. Pursuing this development will allow
researchers to identify clinical ﬁndings, such as outcomes
in cerebral malaria, which have yet to be elucidated in
population-based studies.
As mentioned previously, 500 million cases of malaria
occur each year, causing 1 million deaths [1]. Most of
these cases occur in sub-Saharan Africa, where 22.5 million
people are living with HIV. Thus, millions of people are
likely coinfected with HIV and malaria. Investigating the
eﬀects of coinfection through in vitro coculture models,
animal models, and through clinical studies focused on the
pertinent epidemiological and clinical issues outlined above
is needed to better understand the impact of HIV and
malaria coinfection on public health.
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